Home/Filings/4/0001127602-22-024921
4//SEC Filing

Kirchgraber Paul R 4

Accession 0001127602-22-024921

CIK 0000920148other

Filed

Nov 2, 8:00 PM ET

Accepted

Nov 3, 5:00 PM ET

Size

8.5 KB

Accession

0001127602-22-024921

Insider Transaction Report

Form 4
Period: 2022-11-01
Kirchgraber Paul R
CEO, Covance Drug Development
Transactions
  • Tax Payment

    Common Stock

    2022-11-01$222.56/sh892$198,52413,030 total
  • Exercise/Conversion

    Restricted Stock Unit

    2022-11-012,0072,897 total
    Common Stock (2,007 underlying)
  • Exercise/Conversion

    Common Stock

    2022-11-01+2,00713,922 total
Footnotes (4)
  • [F1]Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.
  • [F2]Stock withholding to satisfy tax withholding obligations.
  • [F3]The Restricted Stock Units vested in three equal annual installments beginning on November 1, 2020 and are now fully vested.
  • [F4]This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

Issuer

LABORATORY CORP OF AMERICA HOLDINGS

CIK 0000920148

Entity typeother

Related Parties

1
  • filerCIK 0001791393

Filing Metadata

Form type
4
Filed
Nov 2, 8:00 PM ET
Accepted
Nov 3, 5:00 PM ET
Size
8.5 KB